Lantheus (LNTH) Q2 Revenue Falls 4%

Lantheus (LNTH) reported Q2 FY2025 results below analyst expectations, with GAAP revenue of $378.0 million and non-GAAP EPS of $1.57, representing year-over-year declines of 4.1% and 12.8% respectively. This underperformance was largely due to an 8.3% decline in sales of its core prostate cancer diagnostic, PYLARIFY, impacted by increased competition and changing Medicare reimbursement rules. Consequently, the company significantly lowered its full-year FY2025 revenue guidance to $1.475 billion-$1.51 billion and non-GAAP EPS guidance to $5.50-$5.70. Despite these near-term headwinds, Lantheus is actively diversifying its portfolio through recent acquisitions of Evergreen Theragnostics and Life Molecular Imaging, advancing its pipeline with assets like MK-6240, and authorized a new $400 million stock repurchase program, signaling a strategic focus on future growth beyond its current core pressures.

Analysis

Lantheus reported a significant miss for its second quarter of fiscal year 2025, with GAAP revenue of $378.0 million falling short of the $387.94 million consensus and declining 4.1% year-over-year. Non-GAAP EPS of $1.57 also missed the $1.68 estimate and fell 12.8% from the prior year. The primary driver for this underperformance was an 8.3% decline in sales of its core prostate cancer diagnostic, PYLARIFY, which is facing intensifying competition and adverse Medicare reimbursement changes. These headwinds prompted a material reduction in full-year FY2025 guidance, with revenue now projected at $1.475 billion–$1.51 billion and adjusted EPS at $5.50–$5.70, resetting near-term growth expectations. In response to these pressures, management is actively executing a strategic pivot to diversify its portfolio. The company recently closed acquisitions of Evergreen Theragnostics and Life Molecular Imaging, adding late-stage and commercial assets in neuroendocrine tumors and Alzheimer's disease diagnostics. This is complemented by positive clinical developments, including its MK-6240 tau PET agent meeting primary endpoints, and a new $400 million stock repurchase authorization intended to support shareholder value through this transitional period.

Key Decisions for Investors

• Investors should anticipate continued share price volatility due to the significant Q2 earnings miss and the substantial downward revision of full-year 2025 guidance, which signals that headwinds in the core PYLARIFY business are expected to persist.
• The investment thesis is shifting from PYLARIFY-driven growth to a longer-term story based on strategic diversification; therefore, closely monitor the integration of recent acquisitions and the regulatory and commercial milestones for pipeline assets like OCTEVY, Neuraceq, and MK-6240.
• Evaluate the new $400 million share repurchase program as a potential support mechanism for the stock, but weigh it against the execution risk of the company's strategic pivot and the deteriorating fundamentals of its primary revenue source.
• Focus on the stabilization of PYLARIFY sales and market share in subsequent quarters, as this remains the key variable for near-term profitability and the company's ability to fund its diversification strategy.